Procaps Group (PROCF) Price & Analysis

Procaps Group S.A. is a global pharmaceutical company engaged in the development, manufacturing, and commercialization of a diverse range of medical solutions. The company's portfolio encompasses branded prescription drugs, addressing numerous therapeutic areas such as women's health, pain relief, dermatological conditions, digestive health, growth and development, cardiovascular issues, vision care, central nervous system disorders, and respiratory ailments. Additionally, it supplies pharmaceutical products for hospital use, including antibiotics, anticoagulants, personal protective equipment, immunosuppressants, oncology treatments, and analgesics. Its consumer healthcare segment features a wide array of over-the-counter (OTC) products across approximately eight therapeutic categories, including gastrointestinal, skincare, cough and cold remedies, pain management, urology, and various vitamins, minerals, and dietary supplements. This expansive offering covers numerous categories like anti-infectives, cardiovascular support, hormonal regulators, metabolic aids, and nervous system treatments. Moreover, Procaps provides comprehensive solutions for diabetes management, encompassing blood glucose monitors, telemonitoring devices, oral anti-diabetic medications, cosmeceuticals, and insulin delivery systems. The firm also operates as a contract drug development and manufacturing (CDMO) provider for other pharmaceutical enterprises, with a recognized specialization in soft gelatin capsule technologies. Established in 1977, Procaps Group S.A. is headquartered in Luxembourg.